Cargando…

Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales

INTRODUCTION: England and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical models of the long-term impact of such a switch compared to ceasing pneumococcal conjugate vaccination altogether....

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yoon Hong, Jit, Mark, Flasche, Stefan, Gay, Nigel, Miller, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396640/
https://www.ncbi.nlm.nih.gov/pubmed/22808073
http://dx.doi.org/10.1371/journal.pone.0039927
_version_ 1782238130692161536
author Choi, Yoon Hong
Jit, Mark
Flasche, Stefan
Gay, Nigel
Miller, Elizabeth
author_facet Choi, Yoon Hong
Jit, Mark
Flasche, Stefan
Gay, Nigel
Miller, Elizabeth
author_sort Choi, Yoon Hong
collection PubMed
description INTRODUCTION: England and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical models of the long-term impact of such a switch compared to ceasing pneumococcal conjugate vaccination altogether. METHODS: A compartmental deterministic model was used to estimate parameters governing transmission of infection and competition between different groups of pneumococcal serotypes prior to the introduction of PCV13. The best-fitting parameters were used in an individual based model to describe pneumococcal transmission dynamics and effects of various options for the vaccination programme change in England and Wales. A number of scenarios were conducted using (i) different assumptions about the number of invasive pneumococcal disease cases adjusted for the increasing trend in disease incidence prior to PCV7 introduction in England and Wales, and (ii) a range of values representing serotype replacement induced by vaccination of the additional six serotypes in PCV13. RESULTS: Most of the scenarios considered suggest that ceasing pneumococcal conjugate vaccine use would cause an increase in invasive pneumococcal disease incidence, while replacing PCV7 with PCV13 would cause an overall decrease. However, the size of this reduction largely depends on the level of competition induced by the additional serotypes in PCV13. The model estimates that over 20 years of PCV13 vaccination, around 5000–62000 IPD cases could be prevented compared to stopping pneumococcal conjugate vaccination altogether. CONCLUSION: Despite inevitable uncertainty around serotype replacement effects following introduction of PCV13, the model suggests a reduction in overall invasive pneumococcal disease incidence in all cases. Our results provide useful evidence on the benefits of PCV13 to countries replacing or considering replacing PCV7 with PCV13, as well as data that can be used to evaluate the cost-effectiveness of such a switch.
format Online
Article
Text
id pubmed-3396640
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33966402012-07-17 Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales Choi, Yoon Hong Jit, Mark Flasche, Stefan Gay, Nigel Miller, Elizabeth PLoS One Research Article INTRODUCTION: England and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical models of the long-term impact of such a switch compared to ceasing pneumococcal conjugate vaccination altogether. METHODS: A compartmental deterministic model was used to estimate parameters governing transmission of infection and competition between different groups of pneumococcal serotypes prior to the introduction of PCV13. The best-fitting parameters were used in an individual based model to describe pneumococcal transmission dynamics and effects of various options for the vaccination programme change in England and Wales. A number of scenarios were conducted using (i) different assumptions about the number of invasive pneumococcal disease cases adjusted for the increasing trend in disease incidence prior to PCV7 introduction in England and Wales, and (ii) a range of values representing serotype replacement induced by vaccination of the additional six serotypes in PCV13. RESULTS: Most of the scenarios considered suggest that ceasing pneumococcal conjugate vaccine use would cause an increase in invasive pneumococcal disease incidence, while replacing PCV7 with PCV13 would cause an overall decrease. However, the size of this reduction largely depends on the level of competition induced by the additional serotypes in PCV13. The model estimates that over 20 years of PCV13 vaccination, around 5000–62000 IPD cases could be prevented compared to stopping pneumococcal conjugate vaccination altogether. CONCLUSION: Despite inevitable uncertainty around serotype replacement effects following introduction of PCV13, the model suggests a reduction in overall invasive pneumococcal disease incidence in all cases. Our results provide useful evidence on the benefits of PCV13 to countries replacing or considering replacing PCV7 with PCV13, as well as data that can be used to evaluate the cost-effectiveness of such a switch. Public Library of Science 2012-07-13 /pmc/articles/PMC3396640/ /pubmed/22808073 http://dx.doi.org/10.1371/journal.pone.0039927 Text en Choi et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Choi, Yoon Hong
Jit, Mark
Flasche, Stefan
Gay, Nigel
Miller, Elizabeth
Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
title Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
title_full Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
title_fullStr Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
title_full_unstemmed Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
title_short Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
title_sort mathematical modelling long-term effects of replacing prevnar7 with prevnar13 on invasive pneumococcal diseases in england and wales
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396640/
https://www.ncbi.nlm.nih.gov/pubmed/22808073
http://dx.doi.org/10.1371/journal.pone.0039927
work_keys_str_mv AT choiyoonhong mathematicalmodellinglongtermeffectsofreplacingprevnar7withprevnar13oninvasivepneumococcaldiseasesinenglandandwales
AT jitmark mathematicalmodellinglongtermeffectsofreplacingprevnar7withprevnar13oninvasivepneumococcaldiseasesinenglandandwales
AT flaschestefan mathematicalmodellinglongtermeffectsofreplacingprevnar7withprevnar13oninvasivepneumococcaldiseasesinenglandandwales
AT gaynigel mathematicalmodellinglongtermeffectsofreplacingprevnar7withprevnar13oninvasivepneumococcaldiseasesinenglandandwales
AT millerelizabeth mathematicalmodellinglongtermeffectsofreplacingprevnar7withprevnar13oninvasivepneumococcaldiseasesinenglandandwales